Literature DB >> 24256397

Valganciclovir in patients with glioblastoma.

Kristoffer Hellstrand, Anna Martner, Tomas Bergström.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24256397     DOI： 10.1056/NEJMc1312413

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  CMV infection and glioma, a highly controversial concept struggling in the clinical arena.

Authors:  Wolfgang Wick; Michael Platten
Journal:  Neuro Oncol       Date:  2014-03       Impact factor: 12.300

Review 2.  Cytomegalovirus and glioblastoma; controversies and opportunities.

Authors:  Sean E Lawler
Journal:  J Neurooncol       Date:  2015-02-15       Impact factor: 4.130

3.  Valganciclovir and bevacizumab for recurrent glioblastoma: A single-institution experience.

Authors:  Chengwei Peng; Jialing Wang; Jarred P Tanksley; Bret C Mobley; Gregory D Ayers; Paul L Moots; Stephen W Clark
Journal:  Mol Clin Oncol       Date:  2015-12-04

Review 4.  The Viral Connection to Glioblastoma.

Authors:  J Ricardo McFaline-Figueroa; Patrick Y Wen
Journal:  Curr Infect Dis Rep       Date:  2017-02       Impact factor: 3.725

5.  Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation.

Authors:  Ceri A Fielding; Rebecca Aicheler; Richard J Stanton; Eddie C Y Wang; Song Han; Sepehr Seirafian; James Davies; Brian P McSharry; Michael P Weekes; P Robin Antrobus; Virginie Prod'homme; Fabien P Blanchet; Daniel Sugrue; Simone Cuff; Dawn Roberts; Andrew J Davison; Paul J Lehner; Gavin W G Wilkinson; Peter Tomasec
Journal:  PLoS Pathog       Date:  2014-05-01       Impact factor: 6.823

Review 6.  Human cytomegalovirus antigens in malignant gliomas as targets for adoptive cellular therapy.

Authors:  Daniel Landi; Meenakshi Hegde; Nabil Ahmed
Journal:  Front Oncol       Date:  2014-11-26       Impact factor: 6.244

7.  Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients.

Authors:  M Bahador; A Gras Navarro; M A Rahman; M Dominguez-Valentin; S Sarowar; E Ulvestad; G Njølstad; S A Lie; E K Kristoffersen; E Bratland; M Chekenya
Journal:  Oncoimmunology       Date:  2017-06-05       Impact factor: 8.110

Review 8.  US28: HCMV's Swiss Army Knife.

Authors:  Benjamin A Krishna; William E Miller; Christine M O'Connor
Journal:  Viruses       Date:  2018-08-20       Impact factor: 5.048
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.